Testing technologies and potential markers for monitoring MRD in AML
| Testing technologies . | Potential markers . | |
|---|---|---|
| MFC | CD2 | CD34 |
| CD4 | CD45 | |
| CD7 | CD56 | |
| CD13 | CD123 | |
| CD15 | CD117 | |
| CD19 | HLA-DR | |
| CD33 | ||
| NGS | NPM1 | |
| RUNX1 | ||
| FLT3-ITD | ||
| IDH1/IDH2 | ||
| RT-qPCR | CBFB/MYH11 | |
| FLT3-ITD | ||
| IDH1/IDH2 | ||
| NPM1 | ||
| RUNX1/RUNX1T1 | ||
| t(10;11) – KMT2A-MLLT10 | ||
| t(11;19) – KMT2A-ELL or KMT2A-MLLT1 | ||
| t(6;11) – KMT2A-MLLT4 | ||
| t(9;11) – KMT2A-MLLT3 | ||
| WT1 | ||
| Testing technologies . | Potential markers . | |
|---|---|---|
| MFC | CD2 | CD34 |
| CD4 | CD45 | |
| CD7 | CD56 | |
| CD13 | CD123 | |
| CD15 | CD117 | |
| CD19 | HLA-DR | |
| CD33 | ||
| NGS | NPM1 | |
| RUNX1 | ||
| FLT3-ITD | ||
| IDH1/IDH2 | ||
| RT-qPCR | CBFB/MYH11 | |
| FLT3-ITD | ||
| IDH1/IDH2 | ||
| NPM1 | ||
| RUNX1/RUNX1T1 | ||
| t(10;11) – KMT2A-MLLT10 | ||
| t(11;19) – KMT2A-ELL or KMT2A-MLLT1 | ||
| t(6;11) – KMT2A-MLLT4 | ||
| t(9;11) – KMT2A-MLLT3 | ||
| WT1 | ||
MLL/MLLT3, mixed lineage leukemia.